Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Welcome to the TNL Beta! We are actively improving this experience.

Share Feedback

Source study found

Story checked

Kidney care trial challenges default dialysis planning for older adults with frailty (opens in a new tab)

medicalxpress.com · 2026-11-05

Short answerEvidenceSource

Short answer

Mixed

Mixed.

2 claims go further than the study. 3 other points were not covered by the paper.

  • 3 supported
  • 2 overstated
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Notice: Analysis is currently derived from study abstracts. Full-text paper analysis capabilities are currently in development.

Share this check

Help improve NewsLink

Tell us what worked or what needs attention in this check.

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Two of eight claims overstate the study. Three of eight check out. Three claims the study doesn't address.

  • 3 supported
  • 2 overstated
  • 3 not covered
Open claim evidence
3

The source study

Preparing for responsive management versus renal dialysis in older people living with kidney failure and frailty or multimorbidity in the UK (Prepare for Kidney Care): a two-arm, superiority, parallel-group, open-label, pragmatic, phase 3, individually randomised controlled trial

Lancet (London, England) · 2026
Open source record (opens in a new tab)Open in Tessa (opens in a new tab)
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

8 claims in this story

Showing all 8 claimsChoose a verdict to focus the list.

Claim 1 of 8OverstatedDialysis should not necessarily be regarded as the default option for older people with kidney failure, according to the first randomized study of its kind in the world.View evidenceHide evidence

Why this verdict

The abstract-profile supports a randomized comparison in older people with kidney failure and frailty/multimorbidity and reports no evidence that either strategy was superior on QALYs. But the headline-level framing that dialysis should not be regarded as the default is a practice recommendation that goes beyond the abstract evidence, and the claim that it was the first randomized study of its kind is not verifiable from the supplied abstract profile. The headline also risks implying equivalence/default-change from a superiority trial with a confidence interval that still allows possible QALY disadvantage for responsive management.

1

Study evidence

No evidence of superiority between prepare for responsive management and prepare for renal dialysis on the primary outcome QALYs over mean 4.5 years follow-up.-0.147 (95% CI -0.350 to 0.056), p=0.16

“a two-arm, superiority, parallel-group, open-label, pragmatic, phase 3, individually randomised controlled trial”
Claim 2 of 8OverstatedThe trial, published in The Lancet, suggests a structured, less medicalized approach without dialysis may offer an alternative without compromising overall length and quality of life.View evidenceHide evidence

Why this verdict

The paper profile supports that a protocolised conservative/responsive-management approach was compared with dialysis preparation and that no superiority was found for either arm on QALYs combining survival and EQ-5D-5L quality of life. However, saying the approach may be offered 'without compromising' overall length and quality of life implies non-inferiority or equivalence, which the abstract-profile does not establish; the trial is described as a superiority trial and the adjusted QALY CI includes possible disadvantage for responsive management.

1

Study evidence

No evidence of superiority between prepare for responsive management and prepare for renal dialysis on the primary outcome QALYs over mean 4.5 years follow-up.-0.147 (95% CI -0.350 to 0.056), p=0.16

“a two-arm, superiority, parallel-group, open-label, pragmatic, phase 3, individually randomised controlled trial”
Claim 3 of 8Not coveredThe study recruited 445 participants from 31 U.K. kidney centers, with around 75% aged 80 or over.View evidenceHide evidence

As stated445 participants; 31 U.K. kidney centers; around 75% aged 80 or over

Why this verdict

The abstract-profile verifies 445 randomized participants and 31 UK kidney centres. It does not provide the reported baseline age distribution that around 75% were aged 80 or over, so that part cannot be checked at abstract depth.

1

Study evidence

No evidence of superiority between prepare for responsive management and prepare for renal dialysis on the primary outcome QALYs over mean 4.5 years follow-up.-0.147 (95% CI -0.350 to 0.056), p=0.16

“a two-arm, superiority, parallel-group, open-label, pragmatic, phase 3, individually randomised controlled trial”
Claim 4 of 8Not coveredOnly 28% of people preparing for dialysis actually started treatment, and participants in both groups were more likely to die from other causes than to require dialysis.View evidenceHide evidence

As stated28%

Why this verdict

The abstract-profile reports deaths and safety outcomes, but it does not report the proportion of dialysis-preparation participants who actually started dialysis, nor a competing-risk statement that participants in both groups were more likely to die from other causes than require dialysis. These details are not verifiable from the supplied abstract profile.

1

Study evidence

No evidence of superiority between prepare for responsive management and prepare for renal dialysis on the primary outcome QALYs over mean 4.5 years follow-up.-0.147 (95% CI -0.350 to 0.056), p=0.16

“a two-arm, superiority, parallel-group, open-label, pragmatic, phase 3, individually randomised controlled trial”
2

Study evidence

Dialysis access complications were significantly lower in the prepare for responsive management group compared with the prepare for renal dialysis group.adjusted incident rate ratio 0.41 (95% CI 0.19 to 0.88)

“Harms (hospital admissions and dialysis access complications) and adverse events (deaths and hospital admissions, by cause) were assessed in the full analysis set.”
Claim 5 of 8Not coveredThe researchers recommend that NHS England, devolved health bodies, the UK Kidney Association and NICE use the findings to support guidance that both treatment approaches should be presented as equally valid options, with decisions made jointly by patients and clinicians.View evidenceHide evidence

Why this verdict

The abstract-profile says the findings provide comparative information relevant to clinical decision-making, but it does not include recommendations to NHS England, devolved bodies, the UK Kidney Association, or NICE, nor does it state that guidance should present both options as 'equally valid.' That recommendation may be in the full article or press material, but it is not verifiable at abstract depth.

1

Study evidence

No evidence of superiority between prepare for responsive management and prepare for renal dialysis on the primary outcome QALYs over mean 4.5 years follow-up.-0.147 (95% CI -0.350 to 0.056), p=0.16

“a two-arm, superiority, parallel-group, open-label, pragmatic, phase 3, individually randomised controlled trial”
Claim 6 of 8SupportedThe Prepare for Kidney Care trial compared dialysis planning with a structured program of care that does not include dialysis in older people with kidney failure and frailty or multimorbidity, looking at quality of life and survival.View evidenceHide evidence

Why this verdict

The profile directly describes the Prepare for Kidney Care trial as a two-arm randomized trial comparing preparation for responsive management, a conservative approach without dialysis/transplant, with preparation for renal dialysis in older adults with kidney failure and frailty or multimorbidity, using QALYs derived from EQ-5D-5L to combine survival and health-related quality of life.

1

Study evidence

No evidence of superiority between prepare for responsive management and prepare for renal dialysis on the primary outcome QALYs over mean 4.5 years follow-up.-0.147 (95% CI -0.350 to 0.056), p=0.16

“a two-arm, superiority, parallel-group, open-label, pragmatic, phase 3, individually randomised controlled trial”
Claim 7 of 8SupportedOver an average follow-up of 4.5 years, neither approach produced better outcomes when length and quality of life were considered together.View evidenceHide evidence

As statedaverage follow-up 4.5 years

Why this verdict

The profile reports mean follow-up of 4.5 years and no evidence of superiority between responsive management and dialysis preparation on the primary QALY outcome, which combined length of life and health-related quality of life.

1

Study evidence

No evidence of superiority between prepare for responsive management and prepare for renal dialysis on the primary outcome QALYs over mean 4.5 years follow-up.-0.147 (95% CI -0.350 to 0.056), p=0.16

“a two-arm, superiority, parallel-group, open-label, pragmatic, phase 3, individually randomised controlled trial”
Claim 8 of 8SupportedThe article says the results do not apply to people already receiving dialysis, or to younger and fitter patients, for whom dialysis and transplantation remain standard care.View evidenceHide evidence

Why this verdict

The supplied profile supports the main applicability caveat: participants were people preparing for treatment with eGFR <15 and were aged 80 or older, or 65–79 with frailty/multimorbidity, so the findings do not directly apply to people already receiving dialysis or to younger and fitter patients. The added statement about dialysis and transplantation remaining standard care for younger/fitter patients is not independently detailed in the abstract profile, but the population limitation itself is supported.

1

Study evidence

No evidence of superiority between prepare for responsive management and prepare for renal dialysis on the primary outcome QALYs over mean 4.5 years follow-up.-0.147 (95% CI -0.350 to 0.056), p=0.16

“a two-arm, superiority, parallel-group, open-label, pragmatic, phase 3, individually randomised controlled trial”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Secondary safety/harms findings: hospital admission rates were similar; dialysis access complications were lower with responsive management; serious adverse events and deaths were reported in both groups.

    The story presentation does not materially report the paper’s safety findings, especially the lower dialysis access complications and similar hospital admissions. It mentions dialysis burden/complications only as contextual concerns rather than as the trial’s reported harms outcomes.

    From Pragmatic individually randomised controlled trial (open-label, superiority); Safety/harms assessment within RCT

  • Selection/generalizability consideration: only 445 of 6120 screened patients, about 7%, were eligible and consented to randomization.

    The story reports the randomized sample size but does not mention the very small proportion of screened patients who entered the trial, which is a material generalizability consideration in the profile.

    From Pragmatic individually randomised controlled trial (open-label, superiority)

  • Open-label design limitation: participants and clinicians were not blinded.

    The story’s caveats mention ethical challenges and withdrawal, but not the open-label design. This is relevant because patient-reported quality-of-life data contributed to the primary QALY endpoint.

    From Pragmatic individually randomised controlled trial (open-label, superiority)

  • Missing-data handling limitation: QALY estimates used imputation for missing EQ-5D-5L values among living participants.

    The story does not mention imputation or the potential influence of missing patient-reported quality-of-life data on QALY estimates.

    From Pragmatic individually randomised controlled trial (open-label, superiority)

  • Harms-analysis limitation: specific harms outcomes were not prespecified, and the abstract provides limited comparative statistics for harms other than dialysis access complications.

    The story does not acknowledge that the harms outcomes had this limitation, which matters when discussing complications or safety comparisons.

    From Safety/harms assessment within RCT

5 things the story did carry across
  • Trial design and population: pragmatic open-label phase 3 individually randomized trial in 31 UK kidney centres, enrolling older adults with kidney failure who were aged ≥80 or aged 65–79 with frailty/multimorbidity.
  • Primary endpoint: QALYs derived from EQ-5D-5L, combining survival and health-related quality of life, analysed by intention to treat with imputation for missing EQ-5D-5L values in living participants.
  • Primary result: mean QALYs were 1.354 with responsive management and 1.472 with dialysis preparation; adjusted mean difference −0.147, 95% CI −0.350 to 0.056, p=0.16, indicating no evidence of superiority for either strategy rather than proven equivalence.
  • Sample size and follow-up: 445 participants randomized and followed for a mean of 4.5 years.
  • Applicability limitation: findings are limited to the trial population and do not directly address people already on dialysis or younger/fitter patients outside the eligibility criteria.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoCompare the effectiveness of preparing for responsive management (protocolised conservative kidney management) versus preparing for renal dialysis on patient-centred outcomes (QALYs from EQ-5D-5L) in older people with kidney failure and frailty/multimorbidity.Pragmatic individually randomised controlled trial (open-label, superiority)Expand

In plain English

Prepare for Kidney Care was a pragmatic, open-label, phase 3 randomized trial in 31 UK kidney centres comparing a protocolised conservative approach (prepare for responsive management) with preparation for renal dialysis in older adults with kidney failure (eGFR <15 mL/min/1.73 m2; age ≥80 or age 65–79 with frailty/multimorbidity). The prespecified primary outcome was QALYs derived from EQ-5D-5L measured from randomisation to Aug 31, 2025 and analysed by intention-to-treat with imputation for missing EQ-5D-5L in living participants. 445 participants were randomised (228 responsive management, 217 dialysis) and followed for a mean of 4.5 years. Mean QALYs were 1.354 (95% CI 1.201–1.508) in the responsive-management group and 1.472 (1.288–1.655) in the dialysis group; adjusted mean difference −0.147 (95% CI −0.350 to 0.056), p=0.16, indicating no evidence of superiority for either strategy on QALYs. Hospital admission rates were similar between groups; dialysis access complications were lower with responsive management (adjusted IRR 0.41, 95% CI 0.19–0.88). Serious adverse events and deaths were reported in both groups (157/228 deaths in responsive management; 136/217 deaths in dialysis).

Key findings

  • No evidence of superiority between prepare for responsive management and prepare for renal dialysis on the primary outcome QALYs over mean 4.5 years follow-up.-0.147 (95% CI -0.350 to 0.056), p=0.16
  • Dialysis access complications were significantly lower in the prepare for responsive management group compared with the dialysis group.Adjusted incident rate ratio 0.41 (95% CI 0.19 to 0.88)
“a two-arm, superiority, parallel-group, open-label, pragmatic, phase 3, individually randomised controlled trial”
What this piece can’t prove
  • Open-label design (no blinding reported).
  • Specific harms outcomes were not prespecified.
  • Imputation was used for missing EQ-5D-5L values in living participants (potential influence on QALY estimates).
  • Only 445 of 6120 screened patients (7%) were eligible and agreed to randomisation (potential selection/generalizability considerations reported in screening data).
2human in vivoCompare safety/harms between the two strategies, including serious adverse events, hospital admissions, and dialysis access complications.Safety/harms assessment within RCTExpand

In plain English

Within the Prepare for Kidney Care randomised trial, harms and adverse events were assessed in the full analysis set. Safety endpoints reported in the abstract include hospital admissions, dialysis access complications, deaths, and hospital admissions by cause. The trial reported counts of serious adverse events and deaths by group, similar hospital admission rates between groups, and a lower rate of dialysis access complications in the prepare for responsive management group (adjusted incident rate ratio 0.41, 95% CI 0.19–0.88) based on 74 events in 36 participants across both groups.

Key findings

  • Dialysis access complications were significantly lower in the prepare for responsive management group compared with the prepare for renal dialysis group.adjusted incident rate ratio 0.41 (95% CI 0.19 to 0.88)
  • Hospital admission rates were reported as similar between the two groups.
“Harms (hospital admissions and dialysis access complications) and adverse events (deaths and hospital admissions, by cause) were assessed in the full analysis set.”
What this piece can’t prove
  • Abstract reports counts and an adjusted IRR for one harms outcome but lacks full methodological detail for harms analyses (e.g., covariates, model specification, denominator/time-at-risk).
  • All information is from the trial abstract; additional details that may appear in the full text (e.g., definitions, adjudication, statistical handling of recurrent events) are not available here.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Preparing for responsive management versus renal dialysis in older people living with kidney failure and frailty or multimorbidity in the UK (Prepare for Kidney Care): a two-arm, superiority, parallel-group, open-label, pragmatic, phase 3, individually randomised controlled trial

Lancet (London, England) · 2026

Deep dive in Tessa (opens in a new tab)Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 37 candidate papers

Selected

Preparing for responsive management versus renal dialysis in older people living with kidney failure and frailty or multimorbidity in the UK (Prepare for Kidney Care): a two-arm, superiority, parallel-group, open-label, pragmatic, phase 3, individually randomised controlled trial

Lancet (London, England) · 2026 · PubMed, Crossref

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

WCN26-3156 MONITORING FREQUENCY AND OUTCOMES IN CKD STAGE G5: A POPULATION-BASED COHORT IN ENGLAND

Kidney International Reports · 2026 · Crossref

Source (opens in a new tab)
Candidate

WCN26-8748 When everyone is counted, how do age, sex, comorbidity, and frailty index associate with who receives kidney replacement therapy?

Kidney International Reports · 2026 · Crossref

Source (opens in a new tab)

And 31 more candidates considered.